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ABSTRACT
Objective: Pen needles used for subcutaneous
injections have gradually become shorter, thinner and
more thin walled, and thereby less robust to patient
reuse. Thus, different needle sizes, alternative tip
designs and needles resembling reuse were tested to
explore how needle design influences ease of insertion,
pain and skin trauma.
Research design and methods: 30 subjects with
injection-treated type 2 diabetes and body mass index
25–35 kg/m2 were included in the single-blinded study.
Each subject received abdominal insertions with 18
different types of needles. All needles were tested twice
per subject and in random order. Penetration force
(PF) through the skin, pain perception on 100 mm
visual analog scale, and change in skin blood
perfusion (SBP) were quantified after the insertions.
Results: Needle diameter was positively related to PF
and SBP (p<0.05) and with a positive pain trend
relation. Lack of needle lubrication and small ‘needle
hooks’ increased PF and SBP (p<0.05) but did not
affect pain. Short-tip, obtuse needle grinds affected PF
and SBP, but pain was only significantly affected in
extreme cases. PF in skin and in polyurethane rubber
were linearly related, and pain outcome was dependent
of SBP increase.
Conclusions: The shape and design of a needle and
the needle tip affect ease of insertion, pain and skin
trauma. Relations are seen across different data
acquisition methods and across species, enabling
needle performance testing outside of clinical trials.
Trial registration number: NCT02531776; results.
INTRODUCTION
There are ∼387 million people with diabetes
mellitus in the world1 and it has been esti-
mated that more than 100 million insulin
injections are performed worldwide every
day.2–4 Thus, it is important that needles for
subcutaneous administration of antidiabetic
drugs are developed to be as safe, pain-free,
and comfortable to use as possible.
Needle manufacturers have through the
years sought to develop needles which cause
less pain and less skin trauma, mainly by
decreasing needle length and diameter;
however, it is a challenge to maintain a
sufﬁciently large inner lumen to keep an
acceptable low injection force. This can
cause the wall thickness to be critically small,
which challenges the robustness of the
needles, and increases the risk of needle tip
damage during, for example, cap removal or
handling. Thus, it is of interest to investigate
how more robust alternatives to the trad-
itional three-grind needle (ie, a needle tip
with three ‘edges’ or grind angles) impact
the user experience. Even though a few
needles with alternate grinds are marketed,
little is known about how needle tip design
inﬂuences ease of insertion through skin,
pain, and tissue trauma.
Needle performance is usually measured
by pain perception of test subjects in a clin-
ical trial5–10 or by mechanical tests with
measurement of penetration force (PF)
through polyurethane rubber (PUR).5 11–13
Significance of this study
What is already known about this subject?
▸ Shorter and thinner needles cause less pain,
thinner needles cause less penetration force,
and a five-grind needle tip has previously shown
to cause less penetration force.
What are the new findings?
▸ Needle diameter and obtuse tip designs were
positively related to skin penetration force, pain,
and skin trauma.
▸ Minor side effects of reuse (worn-off silicone
and small hooks) may not necessarily affect
user experience.
How might these results change the focus of
research or clinical practice?
▸ Smaller needle diameter and obtuse tip designs
should be used in combination to design more
robust needles for people with diabetes.
▸ Since skin trauma and pain perception after
needle insertions relate positively to each other,
skin trauma in animal models can be used to
evaluate performance when developing new
needles.
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However, pain is a subjective measure with many individ-
ual frames of reference causing high data variance,
and clinical trials are costly and time-consuming.
Furthermore, it is unknown if and how PF through PUR
relates to ease of insertion through skin, pain, or other
biological factors.
This study quantitates PF, perceived pain, and the
small skin trauma which occurs at a needle penetration.
Skin trauma was previously explored on pigs by the
authors14 by using Laser Speckle Contrast Analysis
(LASCA) technology15–18 to measure the increase of
skin blood perfusion (SBP) following pen needle inser-
tions, but it is unknown if and how SBP relates to pain
and ease of skin penetration in humans.
The aims of this study were to explore how various
designs of 32G and 34G needles inﬂuence PF, pain, and
SBP, explore the relation between pain and SBP, and
explore the relation between PF in PUR and skin.
RESEARCH DESIGN AND METHODS
Study design
The study was a single-center, one-visit, single-blinded
trial in people with type 2 diabetes, investigating skin PF,
pain, and SBP during needle insertion into the subcutis
on the abdomen with different needle designs.
Subjects
The trial sample consisted of 30 Caucasian men and
women aged 18–70 years with type 2 diabetes, body mass
index (BMI) 25–35 kg/m2, and self-injecting antiglyce-
mic drugs (insulin formulation or glucagon-like peptide
1 agonist) for more than 6 months. Subjects were
excluded if they administered substances which could
inﬂuence pain perception. The subjects’ demographics
were recorded, and information about their daily treat-
ment and regular use of needles was collected.
Randomization
All eligible subjects would receive the same number and
type of needle insertions. Each subject drew a number
on arrival which determined the prerandomized needle
and insertion site sequence.
Needle insertions
With the subject in the supine position, 36 ﬁelds were
drawn—18 on each side of the umbilicus. A screen was
placed above the chest to blind the subject for the
needles. Three test insertions were performed outside of
the ﬁelds in order to prepare the subject and introduce
the evaluation procedure of pain perception. Eighteen
different needles were included in the trial, and all
needles were tested twice on each subject, once on each
side of the abdomen. No substance was injected.
Needles used in the study
Eighteen needles with different designs or properties
were included in the study; see table 1 for details and
illustrations of the needles. Five of the needles were mar-
keted needles; NovoFine 32G tip 6 mm (NF-32),
NovoFine 30G 6 mm (NF-30), NovoFine 28G 12.7 mm
(NF-28; all Novo Nordisk A/S, Bagsværd, Denmark), BD
Micro-Fine Ultra Pentapoint 32G 4 mm (BD-32; Becton,
Dickinson and Company, Franklin Lakes, New Jersey,
USA), and NANOPASS 34G 4 mm (TER-34; Terumo
Corporation, Tokyo, Japan). The BD-32 is a ﬁve-grind
needle (ie, ﬁve edges/grind angles on the needle tip)5
and the TER-34 needle has an asymmetrical three-grind
tip.19 Furthermore, the NF-32 and the TER-34 needles
are both tapered needles with NF-32 being 31G at the
needle base (0.015 mm increase) and TER-34 being 32G
at the needle base (0.06 mm increase). The NF-32
needle has a traditional three-grind needle tip.
Ten needles were custom-designed needles manufac-
tured, lubricated, sterilized and packed by Hart Needles
(Sparta, Michigan, USA). Two were needles with the
same standard three-grind as NF-32, but non-tapered;
32G (HN-32) and 34G (HN-34). Two were three-grind
short-tip needles; 32G (HN3-32) and 34G (HN3-34). Two
were two-grind (ie, two edges/grind angles on the needle
tip) short-tip needles; 32G (HN2-32) and 34G (HN2-34).
Two were one-grind (ie, one edge/grind angle on the
needle tip) short-tip needles; 32G (HN1SH-32) and 34G
(HN1SH-34). Two were one-grind long-tip needles; 32G
(HN1LO-32) and 34G (HN1LO-34).
Although pen needles are for single use only, the
majority of users reuse the needles,20 21 so the silicone is
at risk of being worn-off, and the needle tip might get
hooked from handling, recapping, etc. Therefore, three
of the needles were modiﬁed NF-32 needles which were
either tip damaged with a hook formation or had the
silicone removed. The modiﬁcations were made in a
laminar ﬂow bench, examined under a microscope in a
clean laboratory, and individually repacked and auto-
claved before use in the trial. One had the silicone
coating removed (NOSILIC) by repeated wiping with
82% ethanol swabs (Mediq Danmark A/S, Brøndby,
Denmark). Two needles had hooks, 50 and 150 µm,
respectively. The needle with a 50 µm hook (HOOK50)
was included because a pilot laboratory test of typical
handling errors potentially damaging the needle tip,
including drops, oblique cap removals, and attachment
revealed that the typical hook formation is in the range
40–60 µm. The needle with a large hook of 150 µm
(HOOK150) was included to compare human data with
previous SBP measurements in pigs.14
Assessments
Penetration force
Skin PF was measured using a handheld force gauge
instrument (Advanced Force Gauge 5N, Mecmesin,
Slinfold, UK), connected to a laptop recording the PF
during the needle insertion through the skin. The peak
value of the PF was used for further data analysis. PUR
PF was measured using a Lloyd-Ametek LR5KPLUS
Material Testing Machine (Lloyd Instruments, West
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Sussex, UK). Five of each needle types were included
and peak PFs were used for comparison to peak PFs in
skin. The test procedure is deﬁned in the Chinese stand-
ard BG/T 15811-2001 and previously described.13
Pain
Immediately after each needle insertion the subjects
rated pain intensity on a 0–100 mm visual analog scale
(VAS), where the score 0 indicated no pain and the
score 100 indicated the worst imaginable pain.
Skin blood perfusion
SBP was measured using a LASCA Pericam PSI
(Perimed, Stockholm, Sweden), which was placed above
the skin. Before needle insertions, a baseline of 3 min
was recorded. Three needle insertions were performed
for each recording. Immediately after removal of the
third needle insertion and corresponding pain rating,
the recording was resumed and continued for 15 min.
The 15 min signal recording was chosen based on
previous experience with SBP measurements in pigs,14
and the need for test subjects to remain immobile
during the LASCA recordings in order to minimize
signal noise. The experiments were carried out to meet
the LASCA experimental recommendations outlined by
Mahé et al22 to minimize procedure responsible variation
in the recordings. A dedicated, thermally controlled
room (23±1°C) with constant lighting and low ventila-
tion was used. The data sampling frequency was 10
images per second, and averaged over 10 images to an
effective frame rate of one image per second. The
LASCA data analysis was performed as described in pre-
vious tests on pigs.14 In brief, the mean value of each
baseline recording was used as baseline reference. The
following recorded SBP signal point for the 15 min
recording was compared with this reference, and the
SBP graph for each needle is expressed as a percentage
of the baseline. Area under the curve (AUC) values of
the SBP graphs were used for comparison between the
different needles.
Table 1 Overview of the 18 different needles used in the study
Needle Brand name Gauge
Number
of grinds Modification Design illustration
Marketed needles
NF-32 NovoFine 32G tip (31G
base)
3 –
NF-30
NovoFine 30G 3 –
NF-28 NovoFine 28G 3 –
BD-32 BD Micro-Fine Ultra
Pentapoint
32G 5 – Please see (5)
TER-34 Nanopass 34G (32G
base)
– Please see (25)
Custom-designed needles
HN-32 – 32G 3 – Same tip design as
NF needlesHN-34 – 34G 3 –
HN3-32 – 32G 3 –
HN3-34 – 34G 3 –
HN2-32 – 32G 2 –
HN2-34 – 34G 2 –
HN1LO-32 – 32G 1 –
HN1LO-34 – 34G 1 –
HN1SH-32 – 32G 1 –
HN1SH-34 – 34G 1 –
Modified needles
NOSILIC – 32G tip 3 Worn-off
silicone
Same tip design as
NF-32 needles
HOOK50 – 32G tip 3 50 µm hook
HOOK150
– 32G tip 3 150 µm hook
The needles were marketed, modified or custom-designed, varying in diameter (gauge) and tip design, or with simulated misuse in terms of
worn-off silicone or tip hooks.
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Statistical analysis
Statistical analysis of data was performed using SAS JMP
V.10.0.2 (SAS Institute, Cary, North Carolina, USA).
Comparison of needles with respect to PF and SBP were
expressed as ratios, and therefore data were log-transformed
prior to statistical analysis, and differences on log scale were
back-transformed to the original scale as ratios. Data were
analyzed by an ANOVA model with subject, needle, region
(left/right) and insertion ﬁeld (A-H) as ﬁxed effects, injec-
tion order as a covariate (not included in the model for
SBP), and needle × subject as a random effect. To evaluate
effect relations, a model was ﬁt with pain as response and
subject, needle type, SBP and PF as model effects. Subject
was set as random effect. Linear regression analysis was
made to compare PF in skin and PUR.
Ethics and authorizations
The study received ethical approval by the Regional
Committee of Danish Health Research Ethics
(H-6-2014-042) and health authority approval by the
Danish Health and Medicines Authority ( journal number
2014071250, EUDAMED CIV-ID no. CIV-14-07-012361).
All study participants signed informed consent forms
before entering the study and were free to withdraw from
the study at any time. The study was conducted in accord-
ance with the Declaration of Helsinki of 1964, as revised in
2013, and the guidelines for Good Clinical Practice.
ClinicalTrials.gov number NCT02531776.
RESULTS
Thirty people with type 2 diabetes participated in the
study where 19 (63%) were men, age of 59±6 years
(mean, SD), BMI of 31±3 kg/m2 (mean, SD), diabetes
duration of 13±7 years (mean, SD), injection treatment
duration of 7±5 years (mean, SD), and 26 (87%) of the
test subjects performed all or some of their injections in
the abdomen.
Out of the 1080 needle insertions, 75 were excluded
from the ﬁnal data set. The primary reason was that in
some instances the large hook needle (HOOK150) and
two-grind needles (HN2) did not penetrate the skin,
which accounted for 65 of the exclusions. In addition,
six were excluded because the needle was damaged
before or during insertion, and four were excluded
because of insertion procedure deviations.
Table 2 summarizes the values found for PF, SBP and
pain for all needles in the study, and table 3 represents
the comparisons between the needles.
Needle design influence on effect parameters
Needle diameter
PF and SBP increased with needle diameter (table 3,
‘Diameter’). Pain intensity seemed to increase with
needle diameter, but the difference was not signiﬁcant.
Figure 1 shows the averaged SBP proﬁles in human skin
for the 32G (NF-32), 30G (NF-30), 28G (NF-28), and
large hook (HOOK150) needles, creating peak increases
of 16%, 18%, 25%, and 34%, respectively. All proﬁles
reach their peak between 1 and 4 min after the needle
insertions. For all the custom-designed needles, the 34G
versions also caused smaller peak PF, increase in SBP,
and pain intensities than their 32G equivalents (table 3,
‘Tip design’).
Table 2 Values of different tests for all needles
Needle
PF (N)
LSM (95% CI)
SBP (AUC PU)
LSM (95% CI)
Pain (mm on 100 mm VAS)
LSM (95% CI)
NF-28 0.32 (0.30 to 0.34) 235 (201 to 275) 19.2 (14.2 to 24.1)
NF-30 0.29 (0.27 to 0.30) 161 (138 to 190) 15.0 (10.1 to 20.0)
NF-32 0.25 (0.23 to 0.26) 155 (133 to 182) 14.6 (9.6 to 19.6)
BD-32 0.16 (0.15 to 0.17) 182 (156 to 213) 13.0 (8.1 to 18.0)
TER-34 0.17 (0.16 to 0.19) 152 (130 to 178) 13.3 (8.4 to 18.3)
HN-32 0.48 (0.45 to 0.51) 211 (181 to 247) 15.9 (10.9 to 21.0)
HN-34 0.40 (0.37 to 0.42) 165 (140 to 194) 18.3 (13.3 to 23.4)
HN3-32 1.05 (0.99 to 1.12) 339 (288 to 398) 22.7 (17.5 to 27.8)
HN3-34 0.65 (0.61 to 0,69) 270 (229 to 318) 20.1 (15.0 to 25.2)
HN2-32 1.44 (1.34 to 1.55) 370 (306 to 447) 27.9 (22.0 to 33.8)
HN2-34 0.87 (0.81 to 0.93) 298 (250 to 356) 22.5 (16.8 to 28.3)
HN1LO-32 0.65 (0.61 to 0.69) 300 (256 to 351) 18.1 (13.2 to 23.1)
HN1LO-34 0.64 (0.60 to 0.68) 244 (207 to 289) 14.2 (9.1 to 19.3)
HN1SH-32 1.03 (0.91 to 1.10) 369 (314 to 433) 22.7 (17.5 to 27.9)
HN1SH-34 0.77 (0.72 to 0.82) 267 (227 to 313) 21.2 (16.2 to 26.3)
HOOK50 0.48 (0.45 to 0.51) 215 (184 to 252) 18.1 (15.2 to 23.1)
HOOK150 1.36 (1.27 to 1.46) 386 (321 to 463) 27.1 (21.1 to 33.0)
NOSILIC 0.37 (0.35 to 0.39) 203 (173 to 237) 14.5 (9.5 to 19.4)
PF data measured in Newton, SBP data measured as AUC of recorded PUs, and pain data measured on a 100 mm VAS. All values are given
as the LSM with 95% CI.
AUC, area under the curve; LSM, least square mean; PF, penetration force; PU, perfusion unit; SBP, skin blood perfusion; VAS, visual analog
scale.
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Tip design
The standard three-grind 32G needle (NF-32) caused a
larger peak PF than the asymmetrical three-grind
tapered 34G (TER-34) and the ﬁve-grind 32G (BD-32)
needles (table 3, ‘Tip design, Asymmetrical 3-grind and
3-grind vs 5-grind’). No difference was seen in peak PF
between the BD-32 and the TER-34 needle. The needles
did not differ in SBP or in pain intensity.
In general, all the custom-designed needles caused
larger peak PF (p<0.05) than the 32G needle with stand-
ard three-grind (HN-32; table 3, ‘Tip design’). Apart
from the one-grind long-tip 34G needle (HN1LO-34),
all the custom-designed needles also caused a larger
increase in SBP (p<0.05) than the HN-32 needle. Pain
intensity was only statistically larger for the two-grind
32G needle (HN2-32) compared with the HN-32 needle
(table 3, ‘Tip design, Standard 3-grind vs 2-grind’). The
HN1LO-34 needle was the only needle causing less pain
than the HN-32 needle.
Worn-off silicone
Insertion with a needle with worn-off silicone (NOSILIC)
caused higher PF and increase in SBP than a new fully
lubricated needle (table 3, ‘Worn-off silicone’). Worn-off
silicone did not inﬂuence pain intensity.
Hooks
The small hook of 50 µm (HOOK50) caused higher PF
and SBP than a needle without hook (table 3, ‘Hooks’),
but did not cause higher pain intensity, whereas the
large hook (HOOK150) caused higher PF, larger SBP
increase, and higher pain intensity.
Effect relations
We wished to explore whether needle pain can be pre-
dicted by PF and/or SBP. A least square mean scatter
plot matrix is seen in ﬁgure 2, where a linear approxi-
mation is ﬁtted to show the relations between PF, pain
intensity, and SBP. It is seen that all effects are positively
related. The ﬁtted model estimate that 59% of the inﬂu-
ence on pain comes from intersubject variability. Next
after the subject effect, the SBP is the effect most signiﬁ-
cantly predicting pain (p=0.0002), and then PF
(p=0.0154).
PF in skin versus PUR
PFs of all 18 needles measured higher in PUR than in
skin, and PF in PUR and skin were positively related (PF
in PUR=1.3847×PF in skin+0.1173, R2=0.86, p<0.0001).
Table 3 Needle comparisons for different tests
Estimated difference or ratio
PF SBP Pain
Test Needle 1 Needle 2 Ratio p Value Ratio p Value
Difference
(mm) p Value
Diameter NF-32 NF30 1.16* <0.01 1.04 0.72 0.44 0.90
NF-32 NF28 1.29* <0.01 1.51* <0.01 4.58 0.20
NF-30 NF28 1.11* <0.05 1.45* <0.01 4.13 0.25
Tip design
Asymmetrical 3-grind NF-32 TER-34 0.71* <0.01 0.97 0.85 −1.28 0.72
BD-32 TER-34 1.08 0.06 0.83 0.11 0.28 0.94
3-grind vs 5-grind NF-32 BD-32 0.66* <0.01 1.17 0.16 −1.56 0.66
Standard 3-grind vs short 3-grind HN-32 HN3-32 2.18* <0.01 1.60* <0.01 6.71 0.067
HN-32 HN3-34 1.34* <0.01 1.28* 0.03 4.14 0.26
HN3-32 HN3-34 0.62* <0.01 0.80 0.05 −2.58 0.48
Standard 3-grind vs short 2-grind HN-32 HN2-32 3.00* <0.01 1.75* <0.01 11.97* <0.01
HN-32 HN2-34 1.80* <0.01 1.41* <0.01 6.58 0.09
HN2-32 HN2-34 0.60* <0.01 0.81 0.10 −5.39 0.20
Standard 3-grind vs short 1-grind HN-32 HN1LO-32 1.34* <0.01 1.42* <0.01 2.17 0.55
HN-32 HN1LO-34 1.33* <0.01 1.15 0.22 −1.72 0.64
HN1LO-32 HN1LO-34 0.99 0.89 0.81 0.082 −3.89 0.29
HN-32 HN1SH-32 2.14* <0.01 1.74* <0.01 6.77 0.07
HN-32 HN1SH-34 1.59* <0.01 1.26* 0.04 5.28 0.15
HN1SH-32 HN1SH-34 0.74* <0.01 0.72* <0.01 −1.49 0.69
Worn-off silicone NF-32 NOSILIC 1.51* <0.01 1.30* <0.05 0.137 0.96
Hooks NF-32G HOOK50 1.94* <0.01 1.38* <0.01 3.54 0.33
NF-32G HOOK150 5.55* <0.05 2.48* <0.01 12.45* <0.01
HOOK50 HOOK150 2.86* <0.01 1.79* <0.01 8.91* <0.05
Between-needle comparisons of peak PF and increase of SBP, respectively, are expressed as a ratio. A ratio value higher than 1.00 indicates
that needle 2 caused higher PF or SB than needle 1. Pain comparisons are expressed as a difference in mm on a 100 mm VAS scale.
A positive value indicates that needle 2 rated higher on pain than needle 1.
*Comparison is statistically different (p<0.05).
PF, penetration force; SBP, skin blood perfusion; VAS, visual analog scale.
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Experimental design
Overall, the two inﬂuencing factors on PF, SBP and pain
were the subject variation (p<0.0001 for all assessments)
and the type of needle (p<0.0001, p<0.0001, and
p=0.0003, respectively). Furthermore, pain perception
was not moved over the course of the experiment
(p=0.1596) or inﬂuenced by the area on the abdomen
(p=0.6603), subject gender (p=0.7773), subject age
(p=0.2110), subject BMI (p=0.4962), subject’s usual
needle diameter (p=0.6382), or years with injection
treatment (p=0.4046). The only demographical relation
to any of the assessments was that subject BMI had a
negative relation to SBP (p=0.039)—thus, the larger the
BMI, the less increase in SBP after a needle insertion.
DISCUSSION
Needles for subcutaneous injections are developed to be
as safe, pain-free and as comfortable as possible to the
users. Despite the large market for subcutaneous
needles, the methods for testing needles have not
changed for many years.
This study found that the design of 32G and 34G
needles inﬂuences user experience, in terms of ease of
insertion (PF), skin trauma (SBP increase) and pain.
Furthermore, the ﬁndings show that there is a relation
between the outcomes of the different measured effects.
Effects of needle design
Needle diameter
The three standard three-grind (NF) needles had posi-
tive relations between needle diameter and all the mea-
sured effects, and all the 34G versions of the alternate
grinded needles scored either numerically or signiﬁ-
cantly lower on all effect parameters than their 32G
equivalents. This indicates that no matter how the
needle tip design is, diameter is an important parameter
of the needle with respect to user experience. Our pain
ﬁndings are in line with previous studies showing that
pain decreases with decreasing needle diameter.23 24
Nevertheless, in the present study pain score and
increase in SBP did not differ signiﬁcantly between
NF-32 and NF-30 needles. In our previous pig study, the
magnitude of the SBP increase also related positively to
Figure 1 SBP following
insertions of needles with
different diameters. Averaged
(mean±SEM) SBP profiles
measured 0–15 min after needle
insertion. Only 1 min of the 3 min
baseline is included in the plot.
SBP, skin blood perfusion.
Figure 2 LSM scatter plot matrix with linear fits of relations
between PF, pain, and SBP. PF and SBP values are
log-transformed. LSM, least square mean; PF, penetration
force; SBP, skin blood perfusion.
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needle diameter with no signiﬁcant difference between
NF-32 and NF-30 needles.14 Thus, an agreement was
seen between pain and SBP data in humans and
between SBP data in humans and pigs, which implies a
relation.
Needle tip design
The ﬁve-grind (BD-32) and asymmetrical three-grind
(TER-34) needles caused smaller peak PF in skin and
PUR than the NF-32 needle. This is in line with a previ-
ous study showing a reduced PF in PUR by the BD-32
needles.5 Important to note for these needles are,
however, that not only did they vary in tip design, but
the NF-32 and TER-34 needles are tapered needles, and
the TER-34 is 34G at the tip, so more than one design
factor could potentially inﬂuence the difference in PF.
However, since the peak PF occurs when the needle tip
penetrates the skin,11 13 the base diameter of the
needles should not inﬂuence the peak PF. Therefore,
the differences seen for PF must be due to the different
grinds and/or the tip diameter. Since a smaller PF
would have been expected from a 34G tip needle than
from a 32G needle, the asymmetrical grind on the
TER-34 needle may in itself cause larger PF than the
ﬁve-grind on the BD-32 needle.
The short-tip three-grind (HN3) needles included in
this study were probably too obtuse and created PF and
SBP increases which were larger than the regular three-
grind (HN-32) needle.
The one-grind short-tip (HN1SH) and one-grind
long-tip (HN1LO) needles do not have a sharp tip, but
a rounded sharp edge. The TER-34 needle has an asym-
metrical tip having a partly rounded ‘cutting’ edge,19 so
further investigations of a one-grind needle should be
made. Since there is no sharp tip, the PF was expected
to be higher, which was also the case for all the one-
grind needles. However, the one-grind long-tip needle
in 34G (HN1LO-34) did not differ from the HN-32
needle in either SBP or pain. This indicates that the
length of the needle grind is a decisive parameter in
terms of user experience.
The two-grind needles (HN2) were manufactured to
place a side-grind on the one-grind needle as an
attempt of making a ‘sharp tip’ on the needle. The
angles we chose, however, actually only turned the
needle into a poorer alternative than the one-grind
needle in terms of all effect parameters. To make two-
grind needles perform on par with standard three-grind
needles, the grind angles should be changed.
In general, when excluding the HN2-32 needle, none
of the alternative tip designs caused signiﬁcant differ-
ences in pain intensity from the standard three-grind
needle. This might be due to inability of the subjects to
distinguish between the different needles when needles
are smaller than a certain size. For the alternative tip
designs, the largest difference in pain which did not
meet statistical signiﬁcance was 6.77 mm. It has been
argued that only differences of 10 mm or more on the
100 mm VAS are likely to reﬂect a true change in the
experience of pain.25 26 Thus, our results indicate that
for 32G and 34G needles, the blinded perception of
pain intensity does not differ between needle designs.
Worn-off silicone
When needle reuse was simulated by worn-off silicone
(NOSILIC), the peak PF was higher than on a fully
lubricated needle since friction in the skin is increased.
Also the increase in SBP was higher for the NOSILIC
needle, which might be due to increased friction creat-
ing a ‘pull’ in the skin. Thereby a larger mechanical
stress is exerted on the tissue, leading to a higher
degree of degranulation of mast cells and release of, for
example, histamine and nitric oxide.27 Since both of
these compounds are known vasodilators,27 28 this might
be the cause of the higher increase in SBP. The lack of
silicone also did not inﬂuence pain, indicating that the
sensory nerve endings are not affected by the increased
friction in skin. This is in line with a published study
concluding that needle reuse is not associated with
increased pain,29 but contrary to publications claiming
that lack of cannula lubrication inﬂuences perceptions
of pain.5 30
Hooks
The hooked needles caused higher peak PF than an
undamaged needle, probably due to the missing sharp
tip and a larger surface area puncturing the skin. The
increase in SBP was also higher for both hooked
needles, but only the large hooked needles (HOOK150)
caused higher pain than a new needle. Thus, minor
needle wear, such as worn-off silicone and minor tip
damages, may cause the user to feel increased friction
when inserting and withdrawing the needle, but this will
not necessarily cause more pain.
Effect relations
This study conﬁrmed that pain is very subject-
dependent, but when the intersubject variance was
accounted for, the difference in pain perception was
better predicted by differences in SBP increase around
needle insertion sites than the differences in peak PF in
skin. This means that the SBP increase, which is seen
after a needle insertion, is more likely to correctly
predict needle pain perception than the peak PF in
skin. The reason for the relation between pain and
increase in SBP might be that SBP increase is related to
the amount of tissue trauma that a needle causes, and
that tissue trauma is related to pain. Alternatively, the
signal generation of pain triggers the release of vasodila-
tors locally in the tissue, whereby blood perfusion is
increased in the area.
When comparing the SBP measurements of the
present study to those previously obtained in pigs,14 the
peak SBP increases and the AUC differences between
different diameter needles are very similar in magnitude
and in relation to different needles. Thus, SBP
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measurements on pigs can be used to predict SBP in
humans, enabling future test of needle performance
outside of clinical trials.
Since PF in skin is related to pain perception, and
since PF in skin and PUR are correlated, it seems rea-
sonable to assume that PF in PUR is related to pain per-
ception. PUR PF has very little variance and is thereby
more sensitive to differences in needle design than PF
in skin, which has higher variance. Likewise, PF in skin
is more sensitive to needle design differences than pain
is, as seen for the comparison of the NF-32, BD-32 and
TER-34 needles. Thus, pain cannot be predicted by PF
in PUR alone. However, if PF in PUR is combined with
SBP tests on, for example, pigs, a better prediction of
pain perceptions might result. Furthermore, PF reveals
ease of penetration through skin, which likely adds to
the needle experience as a whole when people with dia-
betes are inserting the needles themselves.
Strengths and limitations
Blinding of test subjects was chosen as an attempt to
make the pain ratings as objective as possible and
unaffected by other circumstances than the actual pain
sensation. Thus, subjects could not see which needle was
used for insertions, and could not see the action of
insertion. On a daily treatment basis, several factors are
likely to add to the ‘pain’ sensation altogether, including
ease of insertion, perceived pain, and possible bleeding
or skin trauma after the insertion. Thus, future clinical
trials of needle testing could, apart from the blinded
testing, include a part where the subjects would perform
insertions of the needles themselves. Here a more
nuanced, but highly relevant, perception of ‘pain’ would
probably emerge.
As expected there was a large intersubject variance in
pain, but this was also the case for SBP and PF data.
All needles were tested twice on all subjects, and PF
and pain perceptions were measured for all insertions,
which provide information of intrasubject variance. The
intrasubject variance is used by the statistical model to
give a better prediction of the data estimates.
To decrease potential variance effects, we chose to use
injection-treated subjects with type 2 diabetes. Subjects
naïve to needle insertions could have added a factor of
needle fear, which potentially could inﬂuence both pain
perception and SBP, since nervousness can affect blood
ﬂow.31 32
CONCLUSION
Needle design in terms of needle diameter and obtuse
tip designs were positively related to skin PF, pain, and
skin trauma. Thus, smaller needle diameter and more
robust alternative tip designs should be used in combin-
ation when developing new needles in order to provide
better user experiences. Minor side effects of reuse
(worn-off silicone and small hooks) may not necessarily
affect the user experience, whereas large hooks increase
PF, skin trauma and pain. PFs in skin and in PUR are lin-
early related. Increased skin trauma and pain perception
after needle insertions positively relate to each other,
enabling future performance testing of needles outside
of a clinical setting.
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